Download PDF
Thromb Haemost 1993; 70(01): 056-059
DOI: 10.1055/s-0038-1646159
State-of-the-Art Lecture
Hemophilia
Schattauer GmbH Stuttgart

Treatment of Patients with Factor VIII and IX Inhibitors

Inga Marie Nilsson
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN
,
Erik Berntorp
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN
,
Christian Freiburghaus
Department for Coagulation Disorders, University of Lund, Malmö General Hospital, Malmö, and Excorim AB, Lund, SWEDEN
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Nilsson IM, Hedner U. Immunosuppressive treatment in hemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol 1976; 16: 369-82
    PubMedGoogle Scholar
  • 2 Lusher JM, Shapiro SS, Palascak JE. et al.: Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies for factor VIII. A multicenter trial. N Engl J Med 1980; 303: 421-25
    CrossrefPubMedGoogle Scholar
  • 3 Sjamsoedin LJM, Heijnen L, Mauser-Bunshcoten EP. et al.: The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A randomised double-blind clinical trial. N Engl J Med 1981; 305: 717-21
    CrossrefPubMedGoogle Scholar
  • 4 Hedner U, Glazer S, Pingel K. et al Successful use of recombinant factor VIIa in a patient with severe hemophilia A during synovectomy. Lancet 1988; 2: 1193
    PubMedGoogle Scholar
  • 5 Macik BG, Hohneker J, Roberts HR. et al.: Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor. Am J Hematol 1989; 32: 232-34
    CrossrefPubMedGoogle Scholar
  • 6 Birch K, Glazer S, Feldstedt M, Hedner U. Clinical results obtained so far with recombinant FVIIa. XX Int Congr World Fed Hemophilia, Athens. 1992 (abstract 160)
    PubMedGoogle Scholar
  • 7 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69: 491-97
    CrossrefPubMedGoogle Scholar
  • 8 Gomperts E, Lawrence J, Liu SL. et al.: Safety and efficacy studies of recombinant tissue factor. Thromb Haemostas 1991; 65: 677
    PubMedGoogle Scholar
  • 9 Kernoff PBA, Thomas ND, Lilley PA. et al.: Clinical experience with polyelectrolyte fractionated porcine factor VIII concentrate in the treatment of haemophiliacs with antibodies for factor VIII. Blood 1984; 63: 31-41
    PubMedGoogle Scholar
  • 10 Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A-Sepharose and specific affinity chromatography for removal of antibodies. In: Factor VIII Inhibitors; AR Liss, New York: 1991. pp. 225-41
    Google Scholar
  • 11 Gjörstrup P, Berntorp E, Larsson L, Nilsson IM. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption. Vox Sang 1991; 61: 244-50
    CrossrefPubMedGoogle Scholar
  • 12 Nilsson IM. The management of hemophilia patients with inhibitors. Transfusion Med Rev 1992; 6: 285-93
    CrossrefPubMedGoogle Scholar
  • 13 Shapiro SS. Antibodies to blood coagulation factors. Clin Haematol 1979; 2: 207-14
    PubMedGoogle Scholar
  • 14 Hultin MB, Shapiro SS, Bowman HS. et al.: Immunosuppressive therapy of factor VIII inhibitors. Blood 1976; 48: 95-108
    PubMedGoogle Scholar
  • 15 Sultan Y, Kazatchkine MD, Maisonneuve O, Nydegger UR. Antiidiotypic suppression of autoantibodies to factor VIII (anti-hemo-philic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 1: 765-68
    PubMedGoogle Scholar
  • 16 Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. In: Factor VIII Inhibitors. Hoyer LW. (ed). AR Liss; New York: 1984. pp. 181-95
    Google Scholar
  • 17 Brackmann HH. 16 years experience with the immuntolerance induction in hemophilia patients at the Bonn Hemophilia Center. XX Int Congr World Fed Hemophilia, Athens. 1992 (abstract 12)
    PubMedGoogle Scholar
  • 18 Mauser-Bunschoten EP, Nilsson IM, Kasper CK. Immune tolerance, a 1990 approach. In: Hemophilia and von Willebrand's Disease in the 1990s. Lusher JM, Kessler CM. (eds) Elsevier Science; New York: 1991. pp. 265-69
    Google Scholar
  • 19 Aznar JA, Jorquera JI, Pieró A. et al.: The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in hemophilia A. Thromb Haemostas 1984; 51: 217-21
    PubMedGoogle Scholar
  • 20 Ewing NP, Sanders NL, Dietrich SL. et al.: Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. JAMA 1988; 259: 65-68
    CrossrefPubMedGoogle Scholar
  • 21 Nilsson IM, Sundqvist SB, Ljung R. et al.: Suppression of secondary antibody by intravenous immunoglobulin in a patient with hemophilia B and antibodies. Scand J Haematol 1983; 30: 458-64
    PubMedGoogle Scholar
  • 22 Nilsson IM, Berntorp E, Zettervall O. Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies. Proc Natl Acad Sci USA 1986; 83: 169-73
    PubMedGoogle Scholar
  • 23 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50
    CrossrefPubMedGoogle Scholar
  • 24 Nilsson IM, Berntorp E, Zettervall O, Dahlbäck B. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. Blood 1990; 75: 378-83
    PubMedGoogle Scholar